Investigating the relationship between NEU1 activity, EV glycosylation and AD progression could yield valuable insights into the disease’s pathophysiology and aid in the identification of novel biomarkers for early diagnosis and monitoring of therapeutic responses. The gene discussed is NEU1; the disease is Alzheimer disease.